Incyte Corporation (NASDAQ:INCY) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.19 by 13 Brokerage Firm. 11 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 1 Brokerage Firms have advised hold.
Other Equity analysts have also commented on the company shares. BMO Capital initiates coverage on Incyte Corporation (NASDAQ:INCY). BMO Capital has a Outperform rating on the shares. The rating by the firm was issued on April 7, 2016.
Incyte Corporation (NASDAQ:INCY): 10 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $93.6 in Incyte Corporation (NASDAQ:INCY). However, the stock price could fluctuate by $ 16.68 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $135 price target with the lower price estimate is calculated at $76
Incyte Corporation (NASDAQ:INCY) witnessed a decline in the market cap on Tuesday as its shares dropped 1.13% or 0.89 points. After the session commenced at $78.84, the stock reached the higher end at $79.4 while it hit a low of $76.04. With the volume soaring to 1,301,253 shares, the last trade was called at $77.6. The company has a 52-week high of $133.62. The company has a market cap of $14,559 million and there are 187,619,380 shares in outstanding. The 52-week low of the share price is $55.
Incyte Corporation has lost 2.73% in the last five trading days and dropped 0.06% in the last 4 weeks. Incyte Corporation is up 12.28% in the last 3-month period. Year-to-Date the stock performance stands at -28.45%.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f